Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2016, Article ID 7531472, 5 pages
http://dx.doi.org/10.1155/2016/7531472
Research Article

The Hasford Score May Predict Molecular Response in Chronic Myeloid Leukemia Patients: A Single Institution Experience

1Department of Hematology and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw, Poland
2Department of Clinical Genetics, Collegium Medicum of Nicolaus Copernicus University, Bydgoszcz, Poland
3Jagiellonian University Hospital, Department of Anaesthesiology and Intensive Care, Krakow, Poland
4Lower Silesian Oncology Center, Department of Radiotherapy, Wroclaw, Poland

Received 17 March 2016; Revised 13 July 2016; Accepted 17 July 2016

Academic Editor: Giuseppe Murdaca

Copyright © 2016 Jarosław Dybko et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Hasford, M. Pfirrmann, R. Hehlmann et al., “A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group,” Journal of the National Cancer Institute, vol. 90, no. 11, pp. 850–858, 1998. View at Publisher · View at Google Scholar · View at Scopus
  2. J. E. Sokal, E. B. Cox, M. Baccarani et al., “Prognostic discrimination in ‘good-risk’ chronic granulocytic leukemia,” Blood, vol. 63, no. 4, pp. 789–799, 1984. View at Google Scholar · View at Scopus
  3. J. Hasford, M. Baccarani, V. Hoffmann et al., “Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score,” Blood, vol. 118, no. 3, pp. 686–692, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. B. Hu and B. N. Savani, “Impact of risk score calculations in choosing front-line tyrosine kinase inhibitors for patients with newly diagnosed chronic myeloid leukemia in the chronic phase,” European Journal of Haematology, vol. 93, no. 3, pp. 179–186, 2014. View at Publisher · View at Google Scholar · View at Scopus
  5. G. Saglio, D.-W. Kim, S. Issaragrisil et al., “Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia,” The New England Journal of Medicine, vol. 362, no. 24, pp. 2251–2259, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. J. E. Cortes, D.-W. Kim, H. M. Kantarjian et al., “Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial,” Journal of Clinical Oncology, vol. 30, no. 28, pp. 3486–3492, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. B. J. Druker, F. Guilhot, S. G. O'Brien et al., “Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia,” The New England Journal of Medicine, vol. 355, no. 23, pp. 2408–2417, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. D. Milojkovic, E. Nicholson, J. F. Apperley et al., “Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia,” Haematologica, vol. 95, no. 2, pp. 224–231, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. J. Hasford, M. Pfirrmann, P. Shepherd et al., “The impact of the combination of baseline risk group and cytogenetic response on the survival of patients with chronic myeloid leukemia treated with interferon alpha,” Haematologica, vol. 90, no. 3, pp. 335–340, 2005. View at Google Scholar · View at Scopus
  10. E. Yamamoto, S. Fujisawa, M. Hagihara et al., “European Treatment and Outcome Study score does not predict imatinib treatment response and outcome in chronic myeloid leukemia patients,” Cancer Science, vol. 105, no. 1, pp. 105–109, 2014. View at Publisher · View at Google Scholar · View at Scopus
  11. E. Jabbour, J. Cortes, A. Nazha et al., “EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience,” Blood, vol. 119, no. 19, pp. 4524–4526, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Breccia, P. Finsinger, G. Loglisci et al., “The EUTOS score identifies chronic myeloid leukeamia patients with poor prognosis treated with imatinib first or second line,” Leukemia Research, vol. 36, no. 9, pp. e209–e210, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Tiribelli, M. Bonifacio, E. Calistri et al., “EUTOS score predicts long-term outcome but not optimal response to imatinib in patients with chronic myeloid leukaemia,” Leukemia Research, vol. 37, no. 11, pp. 1457–1460, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. Z. Tao, B. Liu, Y. Zhao et al., “EUTOS score predicts survival and cytogenetic response in patients with chronic phase chronic myeloid leukemia treated with first-line imatinib,” Leukemia Research, vol. 38, no. 9, pp. 1030–1035, 2014. View at Publisher · View at Google Scholar · View at Scopus
  15. V. S. Hoffmann, M. Baccarani, D. Lindoerfer et al., “The EUTOS prognostic score: review and validation in 1288 patients with CML treated frontline with imatinib,” Leukemia, vol. 27, no. 10, pp. 2016–2022, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Baccarani, G. Saglio, J. Goldman et al., “Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet,” Blood, vol. 108, no. 6, pp. 1809–1820, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Baccarani, J. Cortes, F. Pane et al., “Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet,” Journal of Clinical Oncology, vol. 27, no. 35, pp. 6041–6051, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Baccarani, M. W. Deininger, G. Rosti et al., “European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013,” Blood, vol. 122, no. 6, pp. 872–884, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. J. Gabert, E. Beillard, V. H. J. van der Velden et al., “Standardization and quality control studies of ‘real time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia—a Europe Against Cancer Program,” Leukemia, vol. 17, no. 12, pp. 2318–2357, 2003. View at Publisher · View at Google Scholar · View at Scopus
  20. A. Hochhaus, G. Rosti, N. C. P. Cross et al., “Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study,” Leukemia, vol. 30, no. 1, pp. 57–64, 2016. View at Publisher · View at Google Scholar · View at Scopus
  21. E. Jabbour, H. M. Kantarjian, G. Saglio et al., “Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION),” Blood, vol. 123, no. 4, pp. 494–500, 2014. View at Publisher · View at Google Scholar · View at Scopus
  22. N. P. Shah, F. Guilhot, J. E. Cortes et al., “Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study,” Blood, vol. 123, no. 15, pp. 2317–2324, 2014. View at Publisher · View at Google Scholar · View at Scopus